Design,synthesis and evaluation of new non-ATP competitive Chk1 inhibitor

来源 :2015年全国药物化学学术会议暨第五届中英药物化学学术会议 | 被引量 : 0次 | 上传用户:liongliong517
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Checkpoint kinase 1(Chk1)is a serine/threonine kinase that mediates cell cycle arrest in S-phase or at the G2/M transition.Inhibition of Chk1 would abrogate these checkpoints so that cancer cells,when suffered damage from chemical drug or radiation,would enter mitosis without self-repair,eventually leading to cell death or apoptosis.Therefore,this kind of inhibitor has potential to work as sensitizing agents in cancer therapy.
其他文献
The integration of ultra high-performance liquid chromatography(UHPLC),quadrupole-time of flight-mass spectrometry(Q-TOF-MS),solid phase extraction(SPE),and nuclear magnetic resonance(NMR)is a powerfu
会议
会议
会议
Carbohydrate recognition is a crucial event in many biological processes and has come to the forefront of biological scientific research aiming to uncover the molecular mechanisms of many physiologica
会议
Cyclic α-conotoxin Vc1.1(cVc1.1)(Fig 1)is an orally active peptide with analgesic activity in rat model of neuropathic pain [1].cVc1.1 has two disulfide bonds,which can have three different connectivi
Human Ether-a-go-go-Related Gene(hERG)encodes the main subunit of the rapid rectifier potassium channel that plays a critical role in the repolarization phase of cardiac action potential.Small molecul
蛋白酶体抑制剂是当前药物研究的热点领域之一,20S 蛋白酶体抑制剂已取得了显著进展,19S 蛋白酶体抑制剂近年来也开始受到关注.3,5-二(亚苄基)-4-哌啶酮类化合物(1)是由天然产物姜黄素衍生而来,新近研究表明其具有良好的19S 蛋白酶体抑制作用[1-3].
在发达国家和发展中国家,乳腺癌都是女性最常见的恶性肿瘤之一。在发展中国家,由于预期寿命增加,城市化扩大和采用西方生活方式,乳腺癌发病率正在上升。三阴乳腺癌指雌激素受体(ER)、孕激素受体(PR)及人表皮生长因子受体2(HEK2)均呈阴性的乳腺癌患者。
Breast cancer is one of the most common malignant tumor in women,both in the developed countries and developing countries.Triple-negative breast cancer(TNBC)refers to any breast cancer that does not e